David Mintzer, MD
Hematology & Oncology · Philadelphia, PANPI 1487648846
Payments from drug & device makers
What this record shows
This record is dominated by education: $176 of the $250 with a category attached, or 70.4%. Servier Pharmaceuticals LLC accounts for 63.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $194 and has fallen 73.8% since, to $51 in 2024. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 9 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$159
- GSK$35
- Clovis Oncology, Inc.$28
- Chiesi USA, Inc.$16
- Gilead$12
Across 58 payments — averaging $7653.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$206K
- Daiichi Sankyo Inc.$199K
- Genentech, Inc.$39K
What the payments were for
- Food & beverage$7430%
- Education$17670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 4 | $159 |
| GSK | 1 | $35 |
| Clovis Oncology, Inc. | 2 | $28 |
| Chiesi USA, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$250 in reported general payments places this provider in the 20th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 35 | $503,206 |
| ImbruvicaIbrutinib | 27 | $424,431 |
| CalquenceAcalabrutinib Maleate | 34 | $415,113 |
| IbrancePalbociclib | 27 | $406,359 |
| JakafiRuxolitinib Phosphate | 21 | $354,729 |
| Lenalidomide | 21 | $343,755 |
| RevlimidLenalidomide | 16 | $332,592 |
| NubeqaDarolutamide | 29 | $282,741 |
| JaypircaPirtobrutinib | 12 | $197,102 |
| ErleadaApalutamide | 13 | $183,604 |
| VerzenioAbemaciclib | 14 | $155,451 |
| EliquisApixaban | 39 | $25,783 |
| XareltoRivaroxaban | 26 | $25,706 |
| Anastrozole | 192 | $6,495 |
| Enoxaparin Sodium | 16 | $4,872 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.